Searched for
MAZIAR MIKE DOUSTDAR
Riding high on Wegovy, Novo Nordisk doubled its workforce. Now layoffs loomNovo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's workforce nearly doub...- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- Novo Nordisk CEO warns of layoffs as Wegovy challenge heats upNovo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sa...
- Wegovy maker Novo Nordisk to reduce costs after $95 billion stock lossWegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit warning and new CEO...
- Wegovy maker Novo Nordisk to reduce costs after $95 billion stock lossNovo Nordisk, the maker of Wegovy, will focus on commercial strategy and cost reduction. This decision follows a profit warning and a chang...
- Wegovy maker Novo's profit warning triggers $70 billion share routNovo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO....
- Novo Nordisk stock plunges 23% after cutting sales forecast and naming Mike Doustdar as new CEONVO stock today: Novo Nordisk's stock plummeted over 23% following a reduced full-year sales forecast and the announcement of Maziar Mike D...
- Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEONovo Nordisk has a new CEO. Maziar Mike Doustdar takes the helm. This follows the departure of Lars Fruergaard Jorgensen. The company aims ...
Load More